Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy

ClinicoEconomics and Outcomes Research

Volumn 5, Issue 1, 2013, Pages 87-99

  Mencacci, Claudio ^a   Di Sciascio, Guido ^b   Katz, Pablo ^c   Ripellino, Claudio ^c  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

^b POLICLINICO   (Italy)

^c CSD Medical Research Srl   (Italy)

Author keywords

CEA; Depression; Escitalopram; ICER; Lombardy; SSRI

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; ESCITALOPRAM; LITHIUM; MIRTAZAPINE; PAROXETINE; QUETIAPINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; VENLAFAXINE;

CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SCREENING; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; ITALY; MAJOR DEPRESSION; MONTE CARLO METHOD; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; REMISSION; REVIEW; SENSITIVITY ANALYSIS;

EID: 84873616885     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S39492     Document Type: Review

References (38)

1. Croom K, Plosker G. Spotlight on the pharmacoeconomics of escitalo-pram in depression. CNS Drugs. 2004;18:469-473.
2. Moore JD, Bona JR. Depression and dysthymia. Med Clin North Am. 2001;85:631-644.
3. Girolamo G, Polidori G, Morosini P, et al. Prevalence of common mental disorders in Italy: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004;420:21-27.
4. Colombo G, Di Matteo S. Nel Trattamento della Depressione Maggiore Nelle Diverse Regioni Italiane: Il Ruolo di Venlafaxina [Budget Impact Analysis in the Treatment of Major Depressive Disorder on Italian Regions: The Role of Venlafaxine]. Milan: W.H.E.RE. Medical Press Srl; 2009. Italian.
5. Battaglia A, Dubini A, Mannheimer R, Pancheri P. Depression in the Italian community: epidemiology and socio-economic implications. Int Clin Psycho pharmacol. 2004;19:135-142.
6. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64:1465-1475.
7. Stoudemire A, Frank R, Hedemark N, Kamlet M, Blazer D. The economic burden of depression. Gen Hosp Psychiatry. 1986;8:387-394.
8. Kind P, Sorensen J. The costs of depression. Int Clin Psychopharmacol. 1993;7:191-195.
9. Frank L, Revicki DA, Sorensen SV, et al. The economics of selective serotonin reuptake inhibitors in depression: a critical review. CNS Drugs. 2001;15:59-83.
10. Panzarino PJ, Nash DB. Cost-effective treatment of depression with selec-tive serotonin reuptake inhibitors. Am J Manag Care. 2001;7: 173-184.
11. Revicki DA, Simon GE, Chan K, et al. Depression, health-related quality of life, and medical cost outcomes of receiving recommended levels of antidepressant treatment. J Fam Pract. 1998;47:446-452.
12. Ellis P. Australian and New Zealand clinical practice guidelines for the treatment of depression. Aust N Z J Psychiatry. 2004;38:389-407.
13. National Guideline Clearinghouse: Depression. The treatment and management of depression in adults [webpage on the Internet]. Guideline summary. London, UK: National Institute for Health and Clinical Excellence; 2009. Available from: http://guideline.gov/content.aspx?id=15521. Accessed December 17, 2012.
14. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373:746-758.
15. Trifirò G, Tillati S, Spina E, et al. A nationwide prospective study on prescribing pattern of antidepressant drugs in Italian primary care. Eur J Clin Pharmacol. Epub June 17, 2012.
16. Wessling A, Ramsberg J. Depression: The Review of Antidepressants. Solna, Sweden: The Dental and Pharmaceutical Benefits Agency; 2008. Available from: http://www.tlv.se/Upload/genomgangen/review-antidepressants.pdf. Accessed November 21, 2012.
17. Gaynes B, Rush A, Madhukar T, Wisniewski S, Spencer D, Fava M. The STAR*D study: treating depression in the real world. Cleve Clin J Med. 2008;75:57-66.
18. Gilchrist G, Gunn J. Observational studies of depression in primary care: what do we know? BMC Fam Pract. 2007;8:28.
19. Lothgren M, Hemels M, Francois C, Joensson BA. Cost-effectiveness analysis of escitalopram as first line treatment of depression in Sweden. Primary Care Psychiatry. 2004;9:153-162.
20. Khan A, Khan SR, Leventhal RM, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clini-cal trials: a replication analysis of the Food and Drug Administration Database. Int J Neuropsychopharmacol. 2001;4:113-118.
21. Agenzia Italiana del Farmaco [homepage on the Internet]. Rome: Agenzia Italiana del Farmaco. Available from: http://www.agenziafarmaco.gov.it/. Accessed November 21, 2012.
22. WHOCC [homepage on the Internet]. International language for drug utilization research. Oslo, Norway: World Health Organization Collabo-rating Center for Drug Statistics Methodology; updated May 4, 2012. Available from: http://www.whocc.no/. Accessed November 21, 2012.
23. Sobocki P, Ekman M, Agren H, Runeson B, Jönsson B. The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression. Int J Clin Pract. 2006;60: 791-798.
24. Peveler R, Kendrick T, Buxton M, et al. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine. Health Technol Assess. 2005;9:1-134, iii.
25. Jamison DT, Breman JG, Measham AR, et al, editors. Cost-effectiveness analysis. In: Priorities in Health. Washington, DC: World Bank; 2006. Available from: http://www.ncbi.nlm.nih.gov/books/NBK10253/. Accessed November 21, 2012.
26. Lucioni C, Ravasio R. Come valutare i risultati di uno studio farma-coeconomico? How to evaluate the results of a pharmacoeconomic analysis? PharmacoEconomics - Italian Research Articles. 2004;3: 121-130. Italian.
27. Capri S, Ricciardi W. Advate nel trattamento dell'emofilia A - analisi costo-efficacia della terapia on-demand versus profilassi basata sull'emivita del prodotto. [Advate in the treatment of emofilia A - cost-effectiveness of an on-demand therapy versus a prophylaxis based on the half-life of the product]. Ital J Public Health. 2011;8:61-67. Italian.
28. UK's NICE unlikely to bow to new pricing suggestions. Financial Times. May 10, 2012.
29. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgements. BMJ. 2004;329:224-227.
30. Culyer AJ. Introduction. In: Towse A, Pritchard C, Devlin N, editors. Cost Effectiveness Thresholds: Economic and Ethical Issues. London, UK: Kings Fund and Office of Health Economics; 2002.
31. Palisade Corporation: Maker of Risk and Decision Analysis Software using Monte Carlo Simulation [homepage on the Internet]. Ithaca, NY: Palisade Corporation; 2012. Available from: http://www.palisade.com/. Accessed November 21, 2012.
32. CEA Registry [homepage on the Internet]. Boston, MA: Cost- Effectiveness Analysis Registry. Available from: https://research.tufts-nemc.org/cear4/. Accessed November 21, 2012.
33. Cipriani A, Santilli C, Furukawa TA, et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2009;2:CD006532.
34. Sullivan PW, Valuck R, Saseen J, MacFall HM. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs. 2004;18:911-932.
35. Nuijten M, Brignone M, Marteau F, den Boer J, Hoencamp E. Cost-effectiveness of escitalopram in major depressive disorder in the Dutch health care. Clin Ther. 2012;34:1364-1378.
36. Evans C. The use of consensus methods and expert panels in phar-macoeconomic studies: practical applications and methodological shortcomings. Pharmacoeconomics. 1997;12:121-129.
37. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166:980-991.
38. Garattini L, Castelnuovo E, Lanzeni D, et al. Durata e Costo delle visite in medicina generale. Il progetto DYSCO [Duration and cost of general practitioner visits. The DYSCO project]. Farmeconomia. Health Economics and Therapeutic Pathways. 2003;4:109-114. Italian.